X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition of Affinivax with GSK’s strategy of building a portfolio of specialty medicines and vaccines. It includes a next-generation 24-valent pneumococcal vaccine ASP3772 (AFX3772), which is based on the innovative Multiple Antigen Presenting System (MAPS) platform.
Lead Product(s): AFX3772
Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: $3,300.0 million Upfront Cash: $2,100.0 million
Deal Type: Acquisition August 16, 2022
Details:
Affinivax’s lead MAPS pneumococcal vaccine candidate is AFX3772, which has successfully completed a Phase 2 study in older adults, with a current clinical study in toddlers and planned study in infants.
Lead Product(s): AFX3772
Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
AFX3772, lead vaccine candidate targeting Streptococcus pneumoniae, developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) technology platform, is designed to elicit both B-cell and T-cell immune protection.
Lead Product(s): 24-Valent Pneumococcal Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: AFX3772
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Under the terms of the parties’ new agreement, the clinical development and commercialization of ASP3772, as well as royalties tied to the commercialization of Affinivax’s next generation pneumococcal vaccine products designed to treat Streptococcus pneuomoniae.
Lead Product(s): 24-valent Streptococcus Pneumoniae Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: $65.0 million
Deal Type: Agreement February 28, 2022
Details:
The collaborative program aims to establish preclinical proof of concept for a novel vaccine candidate designed to protect against new COVID-19 variants and that is also suitable for use in low- and middle-income countries.
Lead Product(s): Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Partnership December 13, 2021
Details:
The results from the Phase 2 clinical trial demonstrated that ASP3772 was well tolerated. ASP3772 also exhibited an antibody response to each of the 24 polysaccharides, as well as an additional antibody response to the conserved pneumococcal proteins.
Lead Product(s): ASP3772
Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2021
Details:
Affinivax’s novel vaccine is being developed for the prevention of S. aureus infections, the most common form of staph infections, in high risk adult populations using the company’s Multiple Antigen Presenting System (MAPS™) vaccine technology platform.
Lead Product(s): Staphylococcus aureus vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 09, 2021
Details:
Affinivax’s novel and proprietary MAPS technology platform is designed to enable the development of a new class of vaccines that induce a broad and robust protective immune response to two key immunogenic components.
Lead Product(s): ASP3772
Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Rock Springs Capital
Deal Size: $226.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 08, 2021
Details:
ASP3772 was observed to be safe and well tolerated in adults 18 to 64 years of age. ASP3772 exhibited robust immunogenicity to the 13 pneumococcal serotypes it shares in common with Prevnar13® as well as to an additional 11 serotypes included in ASP3772.
Lead Product(s): ASP3772
Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Proceeds from the Series B financing will be used to continue advancing the company’s MAPS pneumococcal vaccine program and to advance several additional vaccine candidates.
Lead Product(s): MAPS Pneumococcal vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Viking Global Investors
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
